7/27/2023 0 Comments Blue print medicine stockInc’s trailing 12-month revenue is $4.1 billion with a 12.1% net profit margin. Blueprint Medicines Corp does not currently pay a dividend.Ĭurrently, Charles River Laboratories Intl. Analysts expect adjusted earnings to reach $-9.695 per share for the current fiscal year. Year-over-year quarterly sales growth most recently was 1.0%. Blueprint Medicines Corp’s trailing 12-month revenue is $204.6 million with a -284.0% net profit margin. Blueprint Medicines Corp’s stock is NA in 2023, NA in the previous five trading days and up 27.81% in the past year.Ĭurrently, Blueprint Medicines Corp does not have a price-earnings ratio. Inc Stock NewsĪs of June 16, 2023, Blueprint Medicines Corp had a $3.7 billion market capitalization, compared to the Biotechnology & Medical Research median of $103.7 million. Latest Biotechnology & Medical Research and Blueprint Medicines Corp, Charles River Laboratories Intl. The Manufacturing segment includes Microbial Solutions and Biologics Solutions (Biologics). The DSA segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. The RMS segment includes the research models, research model services, and research and cells solutions businesses. The Company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The Company provides research models required in research and development of new drugs, devices, and therapies. is a full service, non-clinical contract research company. It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.Ĭharles River Laboratories International, Inc. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Incīlueprint Medicines Corporation is a global precision therapy company that is inventing medicines for people with cancer and blood disorders. Inc compare based on key financial metrics to determine which better meets your investment needs.Ībout Blueprint Medicines Corp and Charles River Laboratories Intl. Read on to learn how Blueprint Medicines Corp and Charles River Laboratories Intl. Inc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision. If you’re on the fence about investing in Blueprint Medicines Corp or Charles River Laboratories Intl. Sifting through countless of stocks in the Biotechnology & Medical Research industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment.
0 Comments
Leave a Reply. |